Holen Sie sich die Stockscreener-App
5.11
5.14%
0.25
Handel nachbörslich:
5.11
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
What’s the recovery path for long term holders of Acurx Pharmaceuticals Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - Newser
Can Acurx Pharmaceuticals Inc. rally from current levels2025 Market Sentiment & Breakout Confirmation Trade Signals - Newser
How high can Acurx Pharmaceuticals Inc. stock goGap Up & Free Fast Entry Momentum Trade Alerts - Newser
What does recent volatility data suggest for Acurx Pharmaceuticals Inc.Market Activity Summary & Entry Point Strategy Guides - Newser
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attentionBreakout Watch & AI Based Buy/Sell Signal Reports - Newser
Research Analysts Set Expectations for ACXP Q3 Earnings - Defense World
Chart based exit strategy for Acurx Pharmaceuticals Inc.2025 Risk Factors & Expert Curated Trade Setups - Newser
Real time pattern detection on Acurx Pharmaceuticals Inc. stockPortfolio Gains Report & Verified Short-Term Plans - Newser
Intraday pattern recognizer results for Acurx Pharmaceuticals Inc.Bond Market & Consistent Profit Trade Alerts - Newser
Multi asset correlation models including Acurx Pharmaceuticals Inc.Trade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Declines By 95.8% - Defense World
Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program - MSN
Key metrics from Acurx Pharmaceuticals Inc.’s quarterly dataQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Can volume confirm reversal in Acurx Pharmaceuticals Inc.Gap Up & Low Risk Entry Point Guides - Newser
Will a bounce in Acurx Pharmaceuticals Inc. offer an exitPortfolio Return Summary & Weekly High Return Stock Opportunities - Newser
Will Acurx Pharmaceuticals Inc. stock recover after recent dropMarket Performance Report & Weekly Stock Performance Updates - Newser
What risks could impact Acurx Pharmaceuticals Inc. stock performanceTrade Signal Summary & High Accuracy Trade Alerts - Newser
HC Wainwright Forecasts Strong Price Appreciation for Acurx Pharmaceuticals (NASDAQ:ACXP) Stock - Defense World
HC Wainwright Boosts Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target to $31.00 - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals (NASDAQ:ACXP) Given New $31.00 Price Target at HC Wainwright - Defense World
Will Acurx Pharmaceuticals Inc. continue its uptrendRate Hike & Safe Entry Point Alerts - Newser
Acurx Pharmaceuticals stock price target raised to $31 from $8 at H.C. Wainwright - Investing.com Nigeria
Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Raised to $31.00 at HC Wainwright - Defense World
Acurx Pharmaceuticals Reports Positive Q2 Earnings with Promising Clinical Advances and Strategic Financial Management - AInvest
Acurx Pharmaceuticals Inc (ACXP) Q2 2025 Earnings Call Highlights: Strategic Financial ... By GuruFocus - Investing.com Canada
Does Acurx Pharmaceuticals Inc. fit your quant trading model [2025 Stock Rankings]Real-Time Buy Signal Alerts - Newser
Will Acurx Pharmaceuticals Inc. continue its uptrend [Trade Volume Summary]Free Safe Capital Growth Stock Tips - Newser
Acurx Pharmaceuticals Reports Reduced Losses Amid Ongoing R&D Efforts - TipRanks
Is now a turning point for Acurx Pharmaceuticals Inc.Trend Reversal Watch with Entry Signals - Newser
What makes Acurx Pharmaceuticals Inc. stock price move sharply2025 Performance Recap & Stepwise Trade Execution Plans - Newser
H.C. Wainwright Initiates Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Announces Target Price $31 - 富途牛牛
Acurx Pharmaceuticals Q2 2025: Key Contradictions in Funding, Phase III Trials, and Strategic Partnerships - AInvest
Acurx Pharmaceuticals Q2 Earnings: Cost Controls, New Trial Funding, and Advancements in Ibepazolstat Clinical Program - AInvest
Earnings call transcript: Acurx Pharmaceuticals Q2 2025 misses EPS forecast By Investing.com - Investing.com Canada
Transcript : Acurx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Acurx Pharmaceuticals Reports Q2 GAAP EPS of -$1.89, Cash of $6.1mln - AInvest
Acurx Earnings: Net Loss Slashed by Half as Phase 2b Data Published in Lancet Microbe - Stock Titan
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update - Finansavisen
What’s next for Acurx Pharmaceuticals Inc. stock priceInvestment Timing Strategy with Market Filters - Newser
Is Acurx Pharmaceuticals Inc. trading at a discountLow Float Big Mover Alerts - mustnews.co.kr
Using R and stats models for Acurx Pharmaceuticals Inc. forecastingFree Step-by-Step Stock Investment Guide - Newser
Sectors Driving Future Growth for Acurx Pharmaceuticals Inc. Stock2-Day Signal Watch with Forecast Outcome - Newser
Is Acurx Pharmaceuticals Inc. gaining market shareLow Risk High Return Picks - sisaissue.com
Developing predictive dashboards with Acurx Pharmaceuticals Inc. dataTop Stock Picks with Forecast Accuracy - Newser
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):